Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The "lipid sink" refers to a pharmacological and toxicological mechanism in which lipophilic (fat-soluble) toxins are sequestered or partitioned into an administered lipid phase, typically via intravenous lipid emulsion (ILE) therapy. This process reduces the bioavailability of these toxins at their sites of action, thereby mitigating their toxic effects. The sequestration ("lipid sink") mechanism exploits physicochemical properties of both administered therapeutic emulsions and endogenous body compartments to trap harmful fat-soluble substances. This approach underpins modern antidotal strategies against several classes of drug intoxication where conventional therapies may fail.
Partitioning of lipophilic toxins into an administered lipid phase, reducing their concentration at target tissues.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Sequestration of Lipophilic Toxins (Lipid Sink).